metformin

Phase 2/3UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Fatty Liver

Conditions

Fatty Liver

Trial Timeline

Nov 1, 2004 → Jun 1, 2008

NCT ID

NCT00303537

About metformin

metformin is a phase 2/3 stage product being developed by Merck for Fatty Liver. The current trial status is unknown. This product is registered under clinical trial identifier NCT00303537. Target conditions include Fatty Liver.

What happened to similar drugs?

6 of 12 similar drugs in Fatty Liver were approved

Approved (6) Terminated (3) Active (4)

✅Orlistat (Xenical)RocheApproved

✅Xenical, Pegasys, CopegusRocheApproved

✅atorvastatin + Vitamin EPfizerApproved

✅Testosterone Undecanoate + PlaceboBayerApproved

✅Clinolipid + IntralipidBaxterApproved

🔄GODEX + PlaceboCelltrionPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04500678	Phase 2/3	UNKNOWN	Feb 1, 2019	Dec 31, 2022	HIV/AIDS
NCT02017561	Phase 2	Completed	Jan 1, 2014	Dec 1, 2019	Metabolic Syndrome X
NCT02710448	Phase 2	Completed	Jun 1, 2012	Oct 1, 2015	Renal Disorder Associated With Type II Diabetes Mellitus
NCT00390273	Phase 1/2	Completed	Dec 1, 2006	Oct 1, 2007	Hyperlactatemia
NCT00134303	Approved	Completed	Jun 1, 2005	Mar 31, 2006	Obesity
NCT00303537	Phase 2/3	UNKNOWN	Nov 1, 2004	Jun 1, 2008	Fatty Liver

Competing Products

20 competing products in Fatty Liver

See all competitors

Product	Company	Stage	Hype Score
Lanifibranor	Inventiva	Phase 2	29
Low Dose REN001 + High Dose REN001	OnKure Therapeutics	Phase 1	19
GODEX + Placebo	Celltrion	Phase 3	47
placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo	AstraZeneca	Phase 2	35
AZ compound	AstraZeneca	Phase 2	27
Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo	AstraZeneca	Phase 2	35
AZD7503 Intervention	AstraZeneca	Phase 1	29
Efinopegdutide + Semaglutide + Placebo	Merck	Phase 2	35
MK-4074 200 mg + Placebo for MK-4074 + Pioglitazone hydrochloride 30 mg + Placebo for pioglitazone hydrochloride	Merck	Phase 1	29
Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mL	Merck	Phase 2	35
LYS006 + Tropifexor	Novartis	Phase 2	27
LJN452	Novartis	Phase 1	29
LCQ908 + placebo	Novartis	Phase 2	35
Orlistat (Xenical)	Roche	Approved	43
Xenical, Pegasys, Copegus	Roche	Approved	43
Placebo + RO5093151	Roche	Phase 1	29
AMG 609 + Placebo	Amgen	Phase 1	29
Glucagon	Novo Nordisk	Pre-clinical	26
Blood samples	Novo Nordisk	Pre-clinical	18
NNC0194-0499 + NNC0194-0499 + NC0194-0499	Novo Nordisk	Phase 1	29